Preclinical studies showed that inhibition of AXL blocks proliferation of FLT3 mutant and FLT3 wild-type AML cells and also suppresses the leukemic burden of FLT3-ITD+ AML in both a subcutaneous xenograft model and a leukemia engraftment model [16–18]. This evidence concerns the gene FLT3 and leukemia.